LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $98.00.

Several analysts recently commented on the company. Cantor Fitzgerald raised their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Barrington Research upgraded LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $95.00 target price on the stock in a research report on Wednesday, August 6th.

Insider Transactions at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 2,500 shares of LeMaitre Vascular stock in a transaction on Friday, August 8th. The stock was sold at an average price of $94.00, for a total value of $235,000.00. Following the transaction, the director directly owned 2,916 shares in the company, valued at $274,104. The trade was a 46.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO George W. Lemaitre sold 100,000 shares of LeMaitre Vascular stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $93.51, for a total value of $9,351,000.00. Following the transaction, the chief executive officer owned 1,727,003 shares in the company, valued at $161,492,050.53. This represents a 5.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 202,082 shares of company stock valued at $18,249,066 in the last quarter. Company insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of LMAT. Parkside Financial Bank & Trust lifted its position in shares of LeMaitre Vascular by 1,913.3% in the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 287 shares during the last quarter. Opal Wealth Advisors LLC acquired a new stake in shares of LeMaitre Vascular in the first quarter worth about $26,000. NBC Securities Inc. acquired a new stake in shares of LeMaitre Vascular in the first quarter worth about $36,000. Geneos Wealth Management Inc. lifted its position in shares of LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 398 shares during the last quarter. Finally, EverSource Wealth Advisors LLC acquired a new stake in shares of LeMaitre Vascular in the second quarter worth about $47,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Trading Up 0.1%

Shares of NASDAQ LMAT opened at $95.91 on Friday. The company has a market cap of $2.17 billion, a price-to-earnings ratio of 46.56, a price-to-earnings-growth ratio of 2.46 and a beta of 0.79. LeMaitre Vascular has a 12-month low of $71.42 and a 12-month high of $109.58. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. The stock’s 50 day simple moving average is $84.56 and its 200 day simple moving average is $86.53.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.03. The business had revenue of $63.15 million for the quarter, compared to the consensus estimate of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%. The business’s revenue was up 15.0% on a year-over-year basis. During the same quarter last year, the business posted $0.52 EPS. Equities research analysts expect that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st will be given a dividend of $0.20 per share. The ex-dividend date is Thursday, August 21st. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. LeMaitre Vascular’s dividend payout ratio (DPR) is 38.83%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.